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Abstract
Background: Prolonged bisphosphonate treatment might suppress bone remodeling to the extent that normal
bone repair is impaired. While this adverse side effect is usually ascribed to the negative effects of bisphosphonates
on osteoclast survival and function, these effects on osteoblasts are still unclear.
Methods: In the current study, we hypothesized that zoledronate (ZOL) at the μM level might present negative
effects on osteoblast survival and function. In vitro analyses of proliferation, migration and differentiation were
performed on human osteoblast-like cells.
Results: Our results revealed that ZOL treatment dose- and time-dependently induced apoptosis of osteoblasts
after concentrations had reached 10 μM (p < 0.001). The concentrations at which ZOL inhibited osteoblast migration by
50 % were between 10 and 15 μM. Moreover, there was a dose-dependent reduction in the extent of matrix
mineralization, but without a concomitant inhibition of osteogenic differentiation in terms of secreted type I
collagen and osteocalcin and of alkaline phosphatase activity per viable cell. Analyses of the expression of
osteogenic genes confirmed that ZOL at the μM level had no effects on osteogenic differentiation of osteoblasts.
Conclusion: We concluded that ZOL at the μM level affected osteoblast survival and migration, but did not affect
differentiation. The pathophysiological implications of ZOL at the μM level on skeletal disorders need to be investigated
and clarified in the future researches.
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Background
Bisphosphonates are the most widely used and effective
agents against resorption of bone matrix by osteoclasts
and have become an essential part of treatment in pa-
tients with established osteoporosis and in patients with
risk factors for developing osteoporosis [1–3]. Like pyro-
phosphate, bisphosphonates bind strongly to the bone
mineral [4] and are deposited in areas where minerals
are exposed to body fluids, especially focal high-turnover
bone lesions such as the microdamaged skeleton. More-
over, they are particularly resistant to enzymatic and
chemical breakdown in vivo [3]. After focal deposition,
they inhibit bone resorption through the mechanism of in-
ternalization by osteoclasts that interfere with various vital
biochemical processes [1–6]. With such pharmacological
properties that differentiate them from all other anti-
osteoporosis agents, clinicians and researchers deduce that
bisphosphonates might accumulate at the microdamaged
skeletal lesions during long-term treatment that might
lead to the persistence of their effects, both intended and
unintended, even after treatment has been discontinued.
Clinical trials [7, 8] report that treatment with paren-
teral bisphosphonates, particularly zoledronate (ZOL),
significantly decreases both the risk of osteoporotic frac-
tures and the mortality after fragility hip fractures. While
their main effects in vivo are on osteoclast survival and
function, some controversial effects on osteoblasts have
been reported; for example, that bisphosphonates at the
nM-level protect osteoblasts from apoptosis [9, 10]. Evi-
dence from human and animal studies [11–13] also sug-
gests that prolonged treatment with bisphosphonates
suppresses bone formation in vivo. These conflicting re-
sults could be a matter of cumulative-dose exposure sec-
ondary to long-term treatment (μM, not nM level) and
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should be investigated. We therefore hypothesized that
ZOL at the μM level (1) inhibits osteoblast proliferation
and induces osteoblast apoptosis, (2) inhibits osteoblast
migration, and (3) inhibits osteogenic differentiation and
matrix mineralization of osteoblasts.
Methods
Cell lines and cell cultures
We used the human osteoblast-like cell lines MG-63
(CRL-1427) and G-292 (CRL-1423) (American Type
Culture Collection, Rockville, MD, USA), which are
widely used in studies of osteoblast proliferation and dif-
ferentiation. Both cell lines were maintained at 37 °C in
a 5 % CO2 humidified incubator and their cell-specific
culture media (minimal essential medium and McCoy’s
5A medium, respectively), supplemented with 10 % heat-
inactivated fetal bovine serum (FBS), 100 U/ml of peni-
cillin G, and 100 μg/ml of streptomycin, which were
changed every 3 days. ZOL (Novartis Pharma, Basel,
Switzerland) was dissolved in sterile ddH2O and used as
stock solution at a concentration of 1.0 mg/ml. We seri-
ally diluted the stock solution with the cell-specific
media so that the ZOL-conditioned media at different
μM levels were prepared for experiments. Each experi-
ment was repeated at least 3 times. MG-63 and G-292
cells were plated at a density of 6 × 105 and 9 × 105 cells
per well in 6-well plates or at 5 × 103 and 1 × 104 cells
per well in 96-well plates, respectively.
Analyses of cell proliferation, apoptosis, and migration
Cell proliferation was analyzed using XTTassays (Biological
Industries, Kibbutz Beit-Haemek, Israel), for which the cells
were plated in 96-well plates and allowed to attach for 24 h.
The culture media were then changed to the ZOL-
conditioned and control media for a 48-h treatment. An
ELISA plate reader (Thermo Labsystems Multiskan RC,
Vantaa, Finland) was used to measure the absorbance of
the samples at a wavelength of 490 nm.
Apoptosis was detected using chromatin condensation
and fragmentation with H342 dye (Sigma-Aldrich, St.
Louis, MO, USA). Cells were seeded in 6-well plates,
grown for 24 h, and then incubated with the ZOL-
conditioned and control media for 48 and 72 h. H342
dye from the stock solution, originally suspended in
1 mM of ddH2O, was added to the cell suspension for a
total of 10 μM. The cells were then incubated for
60 min, and the apoptotic cells were examined under a
fluorescence microscope.
We studied the effects of ZOL at the μM level on
osteoblast recruitment using a cell migration assay. Cells
were seeded in 6-well plates, allowed to attach for 24 h,
and then incubated with the ZOL-conditioned and con-
trol media for 48 h. After they had been treated, a pip-
ette tip was used to make an I-shaped scratch on the
well. The scratch was followed for its closure and photo-
graphs were taken under a microscope every 12 h for
3 days.
Analyses of cell differentiation and matrix mineralization
We used Alizarin Red-S (ARS) staining to study the ef-
fects of ZOL on matrix mineralization. After they had
been incubated with the ZOL-conditioned and control
media for 7 days, the cells were washed with PBS, and
then fixed in ice-cold 70 % ethanol for at least 1 h. The
ethanol was then removed and the cells were stained
with 40 mM ARS (Sigma-Aldrich) (pH 4.2), for 10 min
at room temperature. The stained cells were then photo-
graphed under a microscope.
Cell differentiation was analyzed using ELISA test kits
(Takara Bio, Otsu, Shiga, Japan; and Invitrogen, Carls-
bad, CA, USA) that were enzyme immunoassays (EIA)
designed to determine type I collagen (COL-1) and
osteocalcin (OCN) directly in biological fluids, which
were the culture supernatants in this case. Samples were
processed and placed in an ELISA plate reader to de-
termine the absorbance at 450 nm against 690 nm (as a
reference). Alkaline phosphatase (ALP) activity was
also quantified (SensoLyte pNPP ALP Assay Kit; Ana-
Spec, San Jose, CA, USA). After they had been treated
with the working solution, the amount of ALP product
(p-nitrophenolate) released by the reaction was mea-
sured using a spectrophotometer at 405 nm. All values
were normalized against the numbers of cells in the
sample.
Analyses of the expression of osteogenic genes
Total RNA was isolated from the cells that were treated
as described above after expansion with normal media
or STEMPRO Osteogenesis Differentiation Medium
(Invitrogen) for 72 h (Total RNA Isolation Kit; Life
Technologies, Gaithersburg, MD, USA). We assessed the
total RNA samples for quality control before using a
PCR assay (Human Osteogenesis RT2 Profiler PCR
Array; SABiosciences [formerly SuperArray Bioscience],
Frederick, MD, USA). Samples were screened for the ex-
pression of 84 genes implicated in differentiation and bone
metabolism. A gene was regarded as constitutively
expressed if it was detected at a cycle threshold (CT) of ≤
35. Genes with CT values > 35 were considered as not
expressed. Fold-change and fold-regulation of each gene
were calculated as the difference in gene expression
between the ZOL-treated and vehicle-treated osteoblasts.
Statistical analysis
SPSS 12.0.1 (SPSS Inc., Chicago, IL, USA) was used for
all analyses: one-way analysis of variance (ANOVA) and
then a Dunnett’s post-hoc for the differences between
the means of the experimental and control groups.
Huang et al. BMC Musculoskeletal Disorders  (2015) 16:355 Page 2 of 7
Quantitative data are means ± standard deviation (SD).
Significance was set at p < 0.05 (two-tailed).
Results
Effects of ZOL on cell proliferation, apoptosis, and
migration of osteoblasts
After a 48-h ZOL treatment, the osteoblast proliferation
rate was dose-dependently downregulated (Fig. 1a).
There were significant differences between the ZOL-
treated and vehicle-treated osteoblasts, with p < 0.001 at
10 and 5 μM and above for MG-63and G-292 cells, re-
spectively. After a 48-h ZOL treatment, a reduction of
more than 30 % was observed while the concentration
reaching the level of 20 μM (Fig. 1b). Besides, ZOL treat-
ment stimulated apoptosis in a dose- and time-
dependent manner at 10 μM and above (p < 0.001)
(Fig. 1c, d). A similar pattern of the effects of ZOL at
the μM level was observed in rat stromal cells (R7500).
(Additional file 1: Figure S1) Cell migration assays of
MG-63 cells reveal that ZOL treatment decreased the
number of cells that migrated into the scratch in a dose-
dependent manner (Fig. 2a, b). The concentrations at
which ZOL inhibited migration by 50 % were between
10 and 15 μM (Fig. 2c).
Effects of ZOL on cell differentiation and matrix
mineralization of osteoblasts
ZOL treatment for 7 days dose-dependently inhibited
bone nodule formation (Fig. 3a). A similar pattern of
the effects of ZOL at the μM level was observed in rat
stromal cells (R7500) again. (Additional file 2: Figure
S2) To clarify the effects of ZOL on osteoblast differen-
tiation and matrix mineralization, we assessed COL-1
and OCN secretion and ALP activity. ZOL treatment
dose-dependently inhibited COL-1 and OCN secretion.
However, there were no significant differences in either
COL-1 or OCN secretion per viable cell between the
ZOL-treated and vehicle-treated osteoblasts. Meanwhile,
A C
B D
Fig. 1 Zoledronate (ZOL) at the μM level presents a dose-dependently inhibitory effect on cellular proliferation of MG-63 and G-292 cells by inducing
apoptosis. Sequential changes of (a) cell proliferation and (b) cell proliferation inhibition ratio of MG-63 and G-292 cells treated with ZOL for
48 h. Sequential changes of apoptotic cells of (c) MG-63 cells and (d) G-292 cells treated with ZOL for 48 h and 72 h. Data are mean ± standard deviation
(SD). N= 3–5 for each experiment; *p< 0.05, **p< 0.001 (vs. the control group; ANOVA)
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there was a dose-dependent decrease of total ALP activity
and that per viable cell (Fig. 3b).
Effects of ZOL on the expression of osteogenic genes
The distribution patterns of constitutive genes were
similar, but after osteogenic induction, gene expression
levels increased for both cell types (Fig. 4a). In total, 25
genes for MG-63 cells, and 33 for G-292 cells, showed a
treated/control (T/C) ratio of > +2 in response to osteo-
genic induction. Of these, Runx2 expression levels in-
creased up to 2.4 times for MG-63 cells, and 5.7 times
for G-292 cells. Additionally, expressions of COL-1
(Col-1α1 and Col-1α2) and bone matrix proteins (ALP,
OCN, and biglycan) were all upregulated in both cell
types. We also investigated the effect of ZOL on the
osteogenic potential of osteoblasts after osteogenic in-
duction. ZOL at different levels did not change the pat-
terns of constitutive gene expression (Fig. 4b). There
was no change in the fold-regulation (T/C ratio > ± 2)
for Runx2, Msx1, NFκB, the SMAD family (SMAD 1–4),
and the TGF/BMP superfamily expression. After ZOL
treatment, the expression levels of ALP were signifi-
cantly lower: a 4.3-fold change for MG-63 cells and a
2.2-fold change for G-292 cells; however, the mRNA
levels of OCN, Col-1α1, Col-1α2 and biglycan were all
unchanged.
Discussion
We found that ZOL at the μM level had a dose-
dependently negative effect on cell proliferation, survival,
migration, and matrix mineralization of both the MG-63
and the G-292 human osteoblast-like cell lines. There
was, however, no significant difference in the expression
and production of osteogenic differentiation markers per
viable cell between the ZOL-treated and vehicle-treated
osteoblasts. The diminished extent of matrix mineralization
A B
C
Fig. 2 Zoledronate (ZOL) at the μM level presents a dose-dependently inhibitory effect on cellular migration of MG-63 cells. a Photographs of
MG-63 cell migration assay. Sequential changes of (b) absolute and (c) relative numbers of migrating MG-63 cells treated with ZOL. Data are
mean ± standard deviation (SD). N = 3–5 for each experiment; *p < 0.05, **p < 0.001 (vs. the control group; ANOVA)
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after ZOL treatment was, therefore, ascribable to decreased
cell proliferation and increased apoptosis, not to decreased
osteogenic differentiation of osteoblasts. Our findings also
provide a clue to the conflicting effects of bisphosphonates
on the survival and function of human osteoblasts [9–13].
Although bisphosphonates at the nM level might have an
anabolic effect on bone [9, 10], bisphosphonates at the μM
level had a negative effect on the survival and function of
osteoblasts.
Bisphosphonates have specific pharmacological prop-
erties; the absence of decay, possible dose-accumulation,
and prolonged retention in focal high-turnover bone le-
sions such as those in microdamaged skeletons [1–3].
This may lead to the persistence of their effects on bone
tissue, both intended and unintended, even after discon-
tinuation of treatment [1]. Although widely used in
clinical practice [7, 8], prolonged bisphosphonate treat-
ment might finally impair bone repair and predispose
bones to atypical fractures [11]. The actual concentra-
tion levels of bisphosphonates that osteoblasts in the
matrix microenvironment are exposed to under pharma-
cological conditions remain unclear; however, an in vivo
study [14] using a fluorescent bisphosphonate analogue,
far-red fluorescent pamidronate, reported that the bone
uptake of bisphosphonates is linear with parentally ad-
ministered doses.
An increasing body of evidence suggests that bispho-
sphonates accumulate in the bone matrix after repeated
dosing and might blunt the anabolic response of para-
thyroid hormone [14–19]. Clinically, the cumulative
dose effects on bone formation might contribute to
osteonecrosis of the jaw in patients treated with a high-
frequency dosing regimen [15] and to atypical fractures
in patients with osteoporosis and a prolonged dosing
regimen [11, 12, 16]. Drug-induced unrepaired micro-
damage in focal high-turnover bone lesions such as the
mandible and proximal femur is thought to be the
cause [14, 20, 21]. These lesions might uptake bispho-
sphonates up to the μM level in the resorption space
even after only a single dose [14, 17]. By using the re-
ported peak local concentrations in the resorption
space, we confirmed that ZOL at the μM level had a
negative effect on the survival and function of human
osteoblasts.
A B
Fig. 3 Zoledronate (ZOL) at the μM level presents a negative effect on matrix mineralization of MG-63 and G-292 cells. a Photographs of
Alizarin red staining of differentiating MG-63 and G-292 cells on the 7th day showed a negative association between ZOL concentrations
and the amount of bone nodule formation. b Sequential changes of the levels of type I collagen, alkaline phosphatase (ALP) and osteocalcin (OCN) of
MG-63 and G-292 cells treated with ZOL. Data are mean ± standard deviation (SD). N = 3–5 for each experiment; *p < 0.05, **p < 0.001 (vs. the control
group; ANOVA)
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AB
Fig. 4 Zoledronate (ZOL) at the μM level does not alter the osteogenic gene expression. a Fold changes of osteogenic gene expression in MG-63
and G-292 cells cultured in normal and osteogenic differentiation media. b Effects of ZOL at the μM level on the fold-regulation of osteogenic
gene expression in MG-63 and G-292 cells post osteogenic induction
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This study has some limitations. First, it was in vitro
and its findings cannot necessarily be generalized to in-
clude in vivo effects. Second, the human osteoblast-like
cell lines used were derived from osteosarcoma because
of their ability to grow for long periods in culture. Third,
the aim of the study was to identify the effects of ZOL
at the μM level on the survival and function of osteo-
blasts but not to investigate mechanisms of interaction.
Randomized prospective controlled clinical trials and in
vitro studies on the regulation mechanisms and
signaling pathways are needed.
Conclusion
ZOL at the μM level might negatively affect bone forma-
tion by directly inhibiting proliferation, survival, and mi-
gration of osteoblasts and then indirectly inhibiting
matrix mineralization. This finding raises the possibility
that atypical fractures might in part be caused by the
negative effects on osteoblasts and, therefore, the unre-
paired microdamage of cortical bone in high-turnover
bone lesions in, for example, the subtrochanteric and di-
aphyseal femur. Further studies are needed to investigate
and clarify the pathophysiological implications of ZOL
at the μM level on related skeletal disorders.
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